West Pharmaceutical Services, Inc. is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company's products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services. The Company's segments include Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment develops commercial and operational strategies across its global network, with specific emphasis on product offerings to biologic, generic and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as an integrated business focused on the design, manufacture and automated assembly of various devices, primarily for pharmaceutical, diagnostic and medical device customers.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Equipment, Supplies & Distribution
- Sub-Industry: Health Care Supplies
- Symbol: NYSE:WST
- CUSIP: 95530610
- Web: www.westpharma.com
Capitalization:- Market Cap: $7.05 billion
- Outstanding Shares: 74,002,000
Average Prices:- 50 Day Moving Avg: $87.78
- 200 Day Moving Avg: $89.57
- 52 Week Range: $70.17 - $99.91
P/E:- Trailing P/E Ratio: 40.86
- Foreward P/E Ratio: 32.61
- P/E Growth: 1.94
Sales & Book Value:- Annual Revenue: $1.54 billion
- Price / Sales: 4.58
- Book Value: $16.79 per share
- Price / Book: 5.67
Dividend:- Annual Dividend: $0.52
- Dividend Yield: 0.6%
Profitability:- EBIDTA: $317.9 million
- Net Margins: 11.42%
- Return on Equity: 14.02%
- Return on Assets: 9.32%
Debt:- Debt-to-Equity Ratio: 0.16%
- Current Ratio: 2.48%
- Quick Ratio: 1.75%
Misc:- Average Volume: 375,528 shs.
- Beta: 1.13
- Short Ratio: 4.24
Frequently Asked Questions for West Pharmaceutical Services (NYSE:WST)
What is West Pharmaceutical Services' stock symbol?
West Pharmaceutical Services trades on the New York Stock Exchange (NYSE) under the ticker symbol "WST."
How often does West Pharmaceutical Services pay dividends? What is the dividend yield for West Pharmaceutical Services?
West Pharmaceutical Services announced a quarterly dividend on Thursday, July 20th. Shareholders of record on Wednesday, October 18th will be paid a dividend of $0.14 per share on Wednesday, November 1st. This represents a $0.56 annualized dividend and a yield of 0.59%. The ex-dividend date of this dividend is Tuesday, October 17th. This is an increase from West Pharmaceutical Services's previous quarterly dividend of $0.13. View West Pharmaceutical Services' Dividend History.
How were West Pharmaceutical Services' earnings last quarter?
West Pharmaceutical Services, Inc. (NYSE:WST) issued its quarterly earnings data on Thursday, July, 27th. The company reported $0.66 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.65 by $0.01. The firm earned $397.60 million during the quarter, compared to analysts' expectations of $406 million. West Pharmaceutical Services had a return on equity of 14.02% and a net margin of 11.42%. The company's quarterly revenue was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.59 EPS. View West Pharmaceutical Services' Earnings History.
When will West Pharmaceutical Services make its next earnings announcement?
What guidance has West Pharmaceutical Services issued on next quarter's earnings?
West Pharmaceutical Services issued an update on its FY17 earnings guidance on Thursday, July, 27th. The company provided EPS guidance of $2.66-2.73 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.67. The company issued revenue guidance of $1.585-1.6 billion, compared to the consensus revenue estimate of $1.61 billion.
Where is West Pharmaceutical Services' stock going? Where will West Pharmaceutical Services' stock price be in 2017?
3 analysts have issued 1 year price targets for West Pharmaceutical Services' shares. Their predictions range from $72.55 to $115.00. On average, they expect West Pharmaceutical Services' stock price to reach $93.78 in the next year. View Analyst Ratings for West Pharmaceutical Services.
Who are some of West Pharmaceutical Services' key competitors?
Some companies that are related to West Pharmaceutical Services include DENTSPLY SIRONA (XRAY), Steris Plc (STE), Bio-Rad Laboratories (BIO), DexCom (DXCM), Hill-Rom Holdings (HRC), VWR Corporation (VWR), Integra LifeSciences Holdings Corporation (IART), ICU Medical (ICUI), LivaNova PLC (LIVN), NuVasive (NUVA), Neogen Corporation (NEOG), Nevro Corp. (NVRO), Haemonetics Corporation (HAE), Halyard Health (HYH), Inogen (INGN), CONMED Corporation (CNMD), MiMedx Group (MDXG) and OraSure Technologies (OSUR).
Who are West Pharmaceutical Services' key executives?
West Pharmaceutical Services' management team includes the folowing people:
- Eric Mark Green, President, Chief Executive Officer, Director
- William J. Federici, Chief Financial Officer, Senior Vice President, Treasurer
- Annette F. Favorite, Chief Human Resource Officer, Senior Vice President
- George Lloyd Miller J.D., Senior Vice President, General Counsel, Corporate Secretary
- Karen A. Flynn, Senior Vice President and Chief Commercial Officer
- David A. Montecalvo, Senior Vice President - Global Operations and Supply Chain
- Eric Resnick, Chief Technology Officer, Vice President
- Daniel Malone, Vice President, Corporate Controller
- Michael A. Anderson, Vice President, Treasurer
- Patrick J. Zenner, Non-Executive Independent Chairman of the Board
Who owns West Pharmaceutical Services stock?
West Pharmaceutical Services' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.86%), BlackRock Inc. (8.40%), Franklin Resources Inc. (5.31%), Neuberger Berman Group LLC (5.06%), State Street Corp (3.39%) and JPMorgan Chase & Co. (2.72%). Company insiders that own West Pharmaceutical Services stock include Daniel Malone, Heino Lennartz, John E Paproski, Karen Flynn, Michael A Anderson, Patrick J Zenner, Paula A Johnson, Thomas W Hofmann, Warwick Bedwell and William J Federici. View Institutional Ownership Trends for West Pharmaceutical Services.
Who sold West Pharmaceutical Services stock? Who is selling West Pharmaceutical Services stock?
West Pharmaceutical Services' stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Eagle Asset Management Inc., Kennedy Capital Management Inc., Neuberger Berman Group LLC, Alliancebernstein L.P., First Trust Advisors LP, Bamco Inc. NY and Hermes Investment Management Ltd.. Company insiders that have sold West Pharmaceutical Services stock in the last year include Daniel Malone, Paula A Johnson and William J Federici. View Insider Buying and Selling for West Pharmaceutical Services.
Who bought West Pharmaceutical Services stock? Who is buying West Pharmaceutical Services stock?
West Pharmaceutical Services' stock was bought by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC, BlackRock Inc., Koch Industries Inc., Renaissance Technologies LLC, FMR LLC, Prudential Financial Inc., AMI Asset Management Corp and Janus Henderson Group PLC. View Insider Buying and Selling for West Pharmaceutical Services.
How do I buy West Pharmaceutical Services stock?
Shares of West Pharmaceutical Services can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is West Pharmaceutical Services' stock price today?
One share of West Pharmaceutical Services stock can currently be purchased for approximately $95.21.
MarketBeat Community Rating for West Pharmaceutical Services (NYSE WST)MarketBeat's community ratings are surveys of what our community members think about West Pharmaceutical Services and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for West Pharmaceutical Services (NYSE:WST) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 3 Buy Ratings |
| Consensus Rating: | Buy (Score: 3.00) |
| Consensus Price Target: | $93.78 (1.51% downside) |
Analysts' Ratings History for West Pharmaceutical Services (NYSE:WST)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 9/15/2017 | Jefferies Group LLC | Upgrade | Hold -> Buy | $96.00 -> $115.00 | High |  |
| 12/23/2016 | Janney Montgomery Scott | Reiterated Rating | Buy | | N/A | |
| 10/28/2016 | Wells Fargo & Company | Upgrade | Market Perform -> Outperform | | N/A | |
(Data available from 9/23/2015 forward)
Earnings History for West Pharmaceutical Services (NYSE:WST)Earnings History by Quarter for West Pharmaceutical Services (NYSE WST)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/25/2017 | | $0.61 | | | | | N/A | |
| 7/27/2017 | Q2 2017 | $0.65 | $0.66 | $406.00 million | $397.60 million | View | N/A | |
| 4/27/2017 | Q1 2017 | $0.55 | $0.81 | $380.42 million | $387.70 million | View | N/A | |
| 2/16/2017 | Q416 | $0.56 | $0.54 | $387.31 million | $382.30 million | View | Listen | |
| 10/27/2016 | Q316 | $0.53 | $0.53 | $371.76 million | $376.70 million | View | Listen | |
| 7/28/2016 | Q216 | $0.56 | $0.59 | $384.58 million | $388.00 million | View | Listen | |
| 4/28/2016 | Q116 | $0.51 | $0.53 | $355.86 million | $362.10 million | View | Listen | |
| 2/18/2016 | Q415 | $0.47 | $0.47 | $364.76 million | $359.70 million | View | Listen | |
| 10/29/2015 | Q315 | $0.43 | $0.44 | $355.90 million | $344.50 million | View | Listen | |
| 7/30/2015 | Q215 | $0.45 | $0.47 | $356.33 million | $359.70 million | View | Listen | |
| 4/30/2015 | Q115 | $0.40 | $0.45 | $346.64 million | $335.90 million | View | Listen | |
| 2/19/2015 | Q414 | $0.46 | $0.45 | $348.33 million | $349.80 million | View | Listen | |
| 10/30/2014 | Q314 | $0.43 | $0.44 | $356.08 million | $355.90 million | View | Listen | |
| 7/31/2014 | Q214 | $0.47 | $0.52 | $368.60 million | $368.90 million | View | N/A | |
| 5/1/2014 | Q114 | $0.41 | $0.38 | $340.90 million | $346.80 million | View | Listen | |
| 2/20/2014 | Q413 | $0.38 | $0.38 | $348.70 million | $342.70 million | View | Listen | |
| 10/31/2013 | Q3 13 | $0.36 | $0.39 | $333.25 million | $341.80 million | View | Listen | |
| 8/1/2013 | Q2 2013 | $0.82 | $0.86 | $349.85 million | $344.50 million | View | Listen | |
| 5/2/2013 | Q1 2013 | $0.86 | $0.87 | $344.20 million | $339.40 million | View | Listen | |
| 2/21/2013 | Q4 2012 | $0.56 | $0.61 | $318.75 million | $321.50 million | View | Listen | |
| 11/1/2012 | Q312 | $0.50 | $0.52 | $306.91 million | $303.80 million | View | N/A | |
| 8/2/2012 | | $0.69 | $0.79 | | | View | N/A | |
| 4/26/2012 | | $0.65 | $0.83 | | | View | N/A | |
| 2/16/2012 | | $0.55 | $0.59 | | | View | N/A | |
| 11/1/2011 | | $0.54 | $0.53 | | | View | N/A | |
| 7/28/2011 | | $0.68 | $0.62 | | | View | N/A | |
| 4/28/2011 | | $0.62 | $0.60 | | | View | N/A | |
| 2/17/2011 | | $0.46 | $0.42 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for West Pharmaceutical Services (NYSE:WST)2017 EPS Consensus Estimate: $2.34
2018 EPS Consensus Estimate: $2.98
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | $0.55 | $0.55 | $0.55 |
| Q2 2017 | 1 | $0.59 | $0.59 | $0.59 |
| Q3 2017 | 1 | $0.54 | $0.54 | $0.54 |
| Q4 2017 | 1 | $0.66 | $0.66 | $0.66 |
| Q1 2018 | 1 | $0.83 | $0.83 | $0.83 |
| Q2 2018 | 1 | $0.81 | $0.81 | $0.81 |
| Q3 2018 | 1 | $0.63 | $0.63 | $0.63 |
| Q4 2018 | 1 | $0.71 | $0.71 | $0.71 |
(Data provided by Zacks Investment Research)
Current Dividend Information for West Pharmaceutical Services (NYSE:WST)| Next Dividend: | 11/1/2017 |
| Annual Dividend: | $0.52 |
| Dividend Yield: | 0.55% |
| Dividend Growth: | 8.40% (3 Year Average) |
| Payout Ratio: | 22.22% (Trailing 12 Months of Earnings)
19.40% (Based on This Year's Estimates)
17.81% (Based on Next Year's Estimates)
|
| Track Record: | 24 Years of Consecutive Dividend Growth |
Dividend History by Quarter for West Pharmaceutical Services (NYSE WST)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 7/20/2017 | Quarterly | $0.14 | 0.6% | 10/17/2017 | 10/18/2017 | 11/1/2017 |
| 5/16/2017 | quarterly | $0.13 | 0.54% | 7/17/2017 | 7/19/2017 | 8/2/2017 |
| 2/16/2017 | Quarterly | $0.13 | | 4/17/2017 | 4/19/2017 | 5/3/2017 |
| 12/14/2016 | quarterly | $0.13 | 0.61% | 1/13/2017 | 1/18/2017 | 2/1/2017 |
| 9/12/2016 | quarterly | $0.13 | | 10/17/2016 | 10/19/2016 | 11/2/2016 |
| 7/6/2016 | Quarterly | $0.12 | | 7/18/2016 | 7/20/2016 | 8/3/2016 |
| 3/4/2016 | Quarterly | $0.12 | | 4/18/2016 | 4/20/2016 | 5/4/2016 |
| 12/17/2015 | Quarterly | $0.12 | | 1/15/2016 | 1/20/2016 | 2/3/2016 |
| 7/15/2015 | quarterly | $0.12 | 0.79% | 10/19/2015 | 10/21/2015 | 11/4/2015 |
| 7/2/2015 | quarterly | $0.11 | 0.76% | 7/20/2015 | 7/22/2015 | 8/5/2015 |
| 2/20/2015 | quarterly | $0.11 | 0.82% | 4/20/2015 | 4/22/2015 | 5/6/2015 |
| 12/22/2014 | quarterly | $0.11 | 0.81% | 1/16/2015 | 1/21/2015 | 2/4/2015 |
| 7/16/2014 | quarterly | $0.11 | | 10/20/2014 | 10/22/2014 | 11/5/2014 |
| 7/16/2014 | quarterly | $0.11 | 1.11% | 10/15/2014 | 10/19/2014 | 11/3/2014 |
| 5/8/2014 | quarterly | $0.10 | 0.94% | 7/21/2014 | 7/23/2014 | 8/6/2014 |
| 2/20/2014 | quarterly | $0.10 | 0.83% | 4/21/2014 | 4/23/2014 | 5/7/2014 |
| 12/19/2013 | quarterly | $0.10 | 0.81% | 1/17/2014 | 1/22/2014 | 2/5/2014 |
| 8/1/2013 | quarterly | $0.20 | | | 10/23/2013 | 11/6/2013 |
| 5/10/2013 | quarterly | $0.19 | 1.16% | 7/22/2013 | 7/24/2013 | 8/7/2013 |
| 3/15/2013 | quarterly | $0.19 | 1.21% | 4/15/2013 | 4/17/2013 | 5/1/2013 |
| 12/27/2012 | quarterly | $0.19 | 1.4% | 1/18/2013 | 1/23/2013 | 2/6/2013 |
(Data available from 1/1/2013 forward)
Insider Trading and Institutional Ownership History for West Pharmaceutical Services (NYSE:WST)Insider Ownership Percentage: 1.90%
Institutional Ownership Percentage: 90.57%
Insider Trades by Quarter for West Pharmaceutical Services (NYSE:WST)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/18/2017 | William J. Federici | CFO | Sell | 54,996 | $95.45 | $5,249,368.20 | |
| 5/2/2017 | Daniel Malone | VP | Sell | 4,124 | $93.31 | $384,810.44 | |
| 12/8/2016 | Patrick J. Zenner | Director | Buy | 332 | $84.53 | $28,063.96 | |
| 10/31/2016 | Paula A. Johnson | Director | Sell | 2,466 | $75.87 | $187,095.42 | |
| 9/6/2016 | Karen Flynn | SVP | Sell | 14,581 | $83.28 | $1,214,305.68 | |
| 8/23/2016 | Paula A Johnson | Director | Sell | 3,042 | $81.55 | $248,075.10 | |
| 6/2/2016 | Daniel Malone | VP | Sell | 3,950 | $74.95 | $296,052.50 | |
| 5/25/2016 | Thomas W Hofmann | Director | Sell | 2,466 | $73.57 | $181,423.62 | |
| 3/1/2016 | Michael A Anderson | VP | Sell | 16,414 | $63.58 | $1,043,602.12 | |
| 2/29/2016 | Thomas W Hofmann | Director | Sell | 3,042 | $62.70 | $190,733.40 | |
| 2/25/2016 | Heino Lennartz | Insider | Sell | 5,680 | $62.47 | $354,829.60 | |
| 2/24/2016 | Heino Lennartz | Insider | Sell | 19,658 | $59.45 | $1,168,668.10 | |
| 2/23/2016 | Paula A. Johnson | Director | Sell | 7,800 | $59.39 | $463,242.00 | |
| 2/22/2016 | Warwick Bedwell | Insider | Sell | 16,042 | $59.52 | $954,819.84 | |
| 11/25/2015 | John E. Paproski | insider | Sell | 17,560 | $63.41 | $1,113,479.60 | |
| 11/12/2015 | Heino Lennartz | Insider | Sell | 3,500 | $61.87 | $216,545.00 | |
| 11/6/2015 | Michael A Anderson | VP | Sell | 3,000 | $62.18 | $186,540.00 | |
| 11/5/2015 | Michael A. Anderson | VP | Sell | 10,000 | $61.98 | $619,800.00 | |
| 11/4/2015 | Daniel Malone | VP | Sell | 4,456 | $61.65 | $274,712.40 | |
| 8/17/2015 | William J Federici | CFO | Sell | 52,678 | $59.72 | $3,145,930.16 | |
| 5/28/2015 | Heino Lennartz | Insider | Sell | 9,584 | $55.00 | $527,120.00 | |
| 5/22/2015 | Karen Flynn | Insider | Sell | 3,091 | $55.24 | $170,746.84 | |
| 5/21/2015 | Eric Mark Green | CEO | Buy | 18,300 | $54.89 | $1,004,487.00 | |
| 5/18/2015 | Karen Flynn | Insider | Sell | 1,909 | $55.00 | $104,995.00 | |
| 5/15/2015 | Donald E Morel Jr | CEO | Sell | 20,000 | $54.29 | $1,085,800.00 | |
| 2/27/2015 | Richard D Luzzi | VP | Sell | 10,000 | $54.85 | $548,500.00 | |
| 2/26/2015 | Michael A Anderson | VP | Sell | 4,682 | $54.93 | $257,182.26 | |
| 2/25/2015 | Heino Lennartz | Insider | Sell | 3,617 | $54.82 | $198,283.94 | |
| 2/24/2015 | John E Paproski | Insider | Sell | 9,282 | $52.87 | $490,739.34 | |
| 2/23/2015 | Heino Lennartz | Insider | Sell | 21,040 | $53.40 | $1,123,536.00 | |
| 2/23/2015 | Patrick J Zenner | Director | Sell | 12,800 | $53.69 | $687,232.00 | |
| 11/26/2014 | Richard D Luzzi | VP | Sell | 8,000 | $52.11 | $416,880.00 | |
| 11/21/2014 | William J Federici | CFO | Sell | 3,000 | $51.22 | $153,660.00 | |
| 11/20/2014 | Donald E Morel Jr | CEO | Sell | 20,000 | $51.30 | $1,026,000.00 | |
| 11/13/2014 | John R Gailey | VP | Sell | 28,000 | $52.37 | $1,466,360.00 | |
| 11/11/2014 | Michael A Anderson | VP | Sell | 4,600 | $51.73 | $237,958.00 | |
| 11/10/2014 | Warwick Bedwell | Insider | Sell | 6,306 | $49.95 | $314,984.70 | |
| 8/21/2014 | Richard D Luzzi | VP | Sell | 10,000 | $44.07 | $440,700.00 | |
| 8/20/2014 | John R Gailey | VP | Sell | 20,000 | $43.96 | $879,200.00 | |
| 8/19/2014 | Michael A Anderson | VP | Sell | 9,800 | $43.41 | $425,418.00 | |
| 8/18/2014 | William J Federici | CFO | Sell | 38,366 | $42.56 | $1,632,856.96 | |
| 8/13/2014 | Heino Lennartz | Insider | Sell | 7,555 | $39.65 | $299,555.75 | |
| 8/11/2014 | Heino Lennartz | Insider | Sell | 11,445 | $40.00 | $457,800.00 | |
| 8/7/2014 | John E Paproski | Insider | Sell | 14,000 | $40.44 | $566,160.00 | |
| 5/30/2014 | Richard D Luzzi | VP | Sell | 22,828 | $42.17 | $962,656.76 | |
| 5/29/2014 | Heino Lennartz | Insider | Sell | 2,000 | $43.00 | $86,000.00 | |
| 2/28/2014 | Heino Lennartz | Insider | Sell | 16,044 | $45.84 | $735,456.96 | |
| 2/26/2014 | Patrick J Zenner | Director | Sell | 12,800 | $46.12 | $590,336.00 | |
| 2/24/2014 | Warwick Bedwell | Insider | Sell | 24,606 | $47.49 | $1,168,538.94 | |
| 11/26/2013 | Donald E Morel Jr | CEO | Sell | 35,000 | $48.60 | $1,701,000.00 | |
| 11/22/2013 | William J Federici | CFO | Sell | 36,000 | $48.34 | $1,740,240.00 | |
| 11/19/2013 | Karen Flynn | Insider | Sell | 5,500 | $47.75 | $262,625.00 | |
| 11/8/2013 | Michael A Anderson | VP | Sell | 9,200 | $46.80 | $430,560.00 | |
| 11/7/2013 | Heino Lennartz | Insider | Sell | 5,102 | $46.70 | $238,263.40 | |
| 11/6/2013 | Michael A Anderson | VP | Sell | 6,000 | $46.53 | $279,180.00 | |
| 11/5/2013 | John R Gailey | VP | Sell | 6,000 | $46.83 | $280,980.00 | |
| 11/5/2013 | Warwick Bedwell | Insider | Sell | 6,304 | $46.84 | $295,279.36 | |
| 11/4/2013 | Richard D Luzzi | VP | Sell | 38,708 | $46.99 | $1,818,888.92 | |
| 8/30/2013 | Donald E Morel Jr | CEO | Sell | 10,000 | $74.46 | $744,600.00 | |
| 8/27/2013 | John R Gailey | VP | Sell | 13,749 | $76.77 | $1,055,510.73 | |
| 8/22/2013 | L Robert Johnson | Director | Sell | 1,883 | $76.81 | $144,633.23 | |
| 8/14/2013 | John E Paproski | Insider | Sell | 6,011 | $79.08 | $475,349.88 | |
| 8/12/2013 | Anthony Welters | Director | Sell | 19,200 | $78.43 | $1,505,856.00 | |
| 8/8/2013 | Michael A Anderson | VP | Sell | 4,300 | $78.00 | $335,400.00 | |
| 5/31/2013 | Michael A Anderson | VP | Sell | 4,000 | $68.94 | $275,760.00 | |
| 5/28/2013 | Donald E Morel Jr | CEO | Sell | 10,000 | $67.87 | $678,700.00 | |
| 5/24/2013 | L Robert Johnson | Director | Sell | 1,700 | $67.47 | $114,699.00 | |
| 5/20/2013 | John R Gailey | VP | Sell | 9,282 | $68.54 | $636,188.28 | |
| 5/17/2013 | L Robert Johnson | Director | Sell | 4,000 | $67.80 | $271,200.00 | |
| 5/8/2013 | L Robert Johnson | Director | Sell | 6,400 | $64.49 | $412,736.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for West Pharmaceutical Services (NYSE:WST)
Latest Headlines for West Pharmaceutical Services (NYSE:WST)
| Source: |
|
| Date | Headline |
|---|
 | Jefferies Group Equities Analysts Raise Earnings Estimates for West Pharmaceutical Services, Inc. (WST)
www.americanbankingnews.com - September 18 at 4:50 AM |
| Zimmer Biomet Holdings (ZBH) and West Pharmaceutical Services (WST) Head-To-Head Review
www.americanbankingnews.com - September 17 at 8:26 AM |
| West Pharmaceutical Services, Inc. (WST) Upgraded by Jefferies Group LLC to "Buy"
www.americanbankingnews.com - September 16 at 12:26 AM |
| Analysts Set $102.75 Target Price for West Pharmaceutical Services, Inc. (WST)
www.americanbankingnews.com - September 15 at 10:36 PM |
| $0.53 EPS Expected for West Pharmaceutical Services, Inc. (WST) This Quarter
www.americanbankingnews.com - September 15 at 6:24 PM |
 | Friday's Top Analyst Upgrades and Downgrades: AbbVie, Bristol-Myers, Eli Lilly ...
247wallst.com - September 15 at 11:34 AM |
 | West Pharmaceutical Services, Inc. – Value Analysis (NYSE:WST) : September 13, 2017
finance.yahoo.com - September 13 at 1:26 AM |
| West Pharmaceutical Services, Inc. breached its 50 day moving average in a Bullish Manner : WST-US : September 11, 2017
finance.yahoo.com - September 12 at 12:20 PM |
| West Pharmaceutical Services, Inc. (WST) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - September 9 at 10:24 AM |
 | West Pharmaceutical Services (WST) Shares Cross Above 200 DMA
www.nasdaq.com - September 1 at 9:05 PM |
| West Pharmaceutical Services, Inc. : WST-US: Dividend Analysis : July 19th, 2017 (record date) : By the numbers : August 24, 2017
finance.yahoo.com - August 25 at 12:46 PM |
| West Announces Fall Investor Conference Schedule
finance.yahoo.com - August 25 at 12:46 PM |
| Brokerages Set $104.00 Target Price for West Pharmaceutical Services, Inc. (WST)
www.americanbankingnews.com - August 25 at 8:54 AM |
| ETFs with exposure to West Pharmaceutical Services, Inc. : August 16, 2017
finance.yahoo.com - August 17 at 9:25 AM |
| See what the IHS Markit Score report has to say about West Pharmaceutical Services Inc.
finance.yahoo.com - August 12 at 8:54 AM |
| Analysts Expect West Pharmaceutical Services, Inc. (NYSE:WST) Will Post Earnings of $0.53 Per Share
www.americanbankingnews.com - August 9 at 8:24 PM |
| Analyzing West Pharmaceutical Services (NYSE:WST) & OraSure Technologies (OSUR)
www.americanbankingnews.com - August 6 at 12:28 PM |
| BidaskClub Downgrades West Pharmaceutical Services, Inc. (NYSE:WST) to Strong Sell
www.americanbankingnews.com - August 3 at 1:12 PM |
| West Pharmaceutical Services, Inc. :WST-US: Earnings Analysis: Q2, 2017 By the Numbers : August 2, 2017
finance.yahoo.com - August 3 at 8:57 AM |
| West Pharmaceutical Services, Inc. to Post Q3 2017 Earnings of $0.54 Per Share, Jefferies Group Forecasts (NYSE:WST)
www.americanbankingnews.com - July 31 at 7:03 AM |
| Edited Transcript of WST earnings conference call or presentation 27-Jul-17 1:00pm GMT
finance.yahoo.com - July 29 at 8:49 AM |
| West Pharmaceutical Services Becomes Oversold (WST)
www.nasdaq.com - July 28 at 10:04 AM |
| West Pharmaceutical Services, Inc. (WST) Downgraded by BidaskClub
www.americanbankingnews.com - July 27 at 5:14 PM |
| West Pharmaceutical Services, Inc. (WST) Issues Earnings Results
www.americanbankingnews.com - July 27 at 1:47 PM |
| West Pharmaceutical Services, Inc. (NYSE:WST) Releases FY17 Earnings Guidance
www.americanbankingnews.com - July 27 at 11:51 AM |
| West Announces Second-Quarter 2017 Results
finance.yahoo.com - July 27 at 9:38 AM |
| West Pharmaceutical misses Street 2Q forecasts
finance.yahoo.com - July 27 at 9:38 AM |
| Zacks: West Pharmaceutical Services, Inc. (WST) Given $107.50 Average Target Price by Analysts
www.americanbankingnews.com - July 25 at 9:59 AM |
| West Pharmaceutical Services, Inc. (WST) Announces Dividend Increase - $0.14 Per Share
www.americanbankingnews.com - July 21 at 12:20 PM |
 | Global Pharmaceutical Packaging Market 2014 - 2025
www.finanznachrichten.de - July 21 at 8:50 AM |
| Zacks: Brokerages Expect West Pharmaceutical Services, Inc. (NYSE:WST) to Announce $0.65 EPS
www.americanbankingnews.com - July 20 at 2:32 PM |
| West Announces Increase to Quarterly Dividend
finance.yahoo.com - July 20 at 9:16 AM |
| Zacks Investment Research Lowers West Pharmaceutical Services, Inc. (NYSE:WST) to Sell
www.americanbankingnews.com - July 19 at 11:18 AM |
| West Pharmaceutical Services, Inc. (NYSE:WST) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - July 19 at 8:53 AM |
| Gerresheimer licenses syringe safety solution from West
finance.yahoo.com - July 17 at 12:31 PM |
| West Pharmaceutical Services, Inc. (WST) Ex-Dividend Date Scheduled for July ...
www.nasdaq.com - July 15 at 9:44 AM |
| Dividend Coverage: This Healthcare Company has Raised Dividend for 24 Consecutive Years; Will Trade Ex-Dividend on July 17, 2017
finance.yahoo.com - July 14 at 10:04 AM |
| BidaskClub Lowers West Pharmaceutical Services, Inc. (WST) to Hold
www.americanbankingnews.com - July 5 at 3:18 PM |
| West Pharmaceutical Services, Inc. (NYSE:WST) Downgraded by Zacks Investment Research
www.americanbankingnews.com - July 4 at 11:42 AM |
| West Pharmaceutical Services, Inc. – Value Analysis (NYSE:WST) : July 3, 2017
finance.yahoo.com - July 4 at 8:53 AM |
| Jefferies Group Equities Analysts Decrease Earnings Estimates for West Pharmaceutical Services, Inc. (NYSE:WST)
www.americanbankingnews.com - July 3 at 7:59 AM |
| West Pharmaceutical Services, Inc. breached its 50 day moving average in a Bearish Manner : WST-US : June 30, 2017
finance.yahoo.com - July 1 at 9:10 AM |
| West Pharmaceutical Services, Inc. (WST) to Post Q4 2017 Earnings of $0.66 Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - June 30 at 10:10 AM |
| Head-To-Head Review: West Pharmaceutical Services (WST) vs. Covidien (COV)
www.americanbankingnews.com - June 28 at 8:38 PM |
| West Pharmaceutical Services, Inc. (WST) Expected to Announce Quarterly Sales of $405.33 Million
www.americanbankingnews.com - June 28 at 11:56 AM |
| Analysts Expect West Pharmaceutical Services, Inc. (WST) to Announce $0.65 Earnings Per Share
www.americanbankingnews.com - June 26 at 12:32 PM |
| West Pharmaceutical Services, Inc. (WST) Upgraded at Zacks Investment Research
www.americanbankingnews.com - June 23 at 7:56 AM |
| West Pharmaceutical Services, Inc. (WST) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - June 22 at 9:52 AM |
| West Pharmaceutical Services, Inc. (WST) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - June 16 at 9:26 AM |
| West Pharmaceutical Services, Inc. (WST) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - June 13 at 8:32 PM |
West Pharmaceutical Services (WST) Chart for Saturday, September, 23, 2017
